Taken together, Xanthoxylin demonstrates potential as a therapeutic agent by modulating the NF-κB and Nrf2 pathways and improving survival rates through a reduction in TNF-α and IL-6 levels in ARDS conditions. Here, IL6 is linked to acute respiratory distress syndrome.